Byron, Sara A <br/><br/>
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.  [electronic resource] 

 -  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society  Nov 2012 
 - 1517-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1525-1438 
<br/><br/><label>Standard No.: </label>10.1097/IGC.0b013e31826f6806  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Endometrioid--drug therapy<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Evaluation, Preclinical<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Endometrial Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Mutation--physiology<br/>Paclitaxel--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 2--genetics<br/>Receptors, Fibroblast Growth Factor--antagonists & inhibitors<br/>Tumor Cells, Cultured